Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
about
New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney DiseaseSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusIncreased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysUpdate on the treatment of type 2 diabetes mellitusSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureThe Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart FailureProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusSeasonal Variation in the Daily Urinary Sodium Excretion in Outpatients from the Morioka Region of Northern JapanA randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesDapagliflozinDapagliflozin for the treatment of type 2 diabetes: a review of the literatureSodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsDapagliflozin in patients with type 2 diabetes mellitus.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitusGlucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesSodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume RetentionMechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusCardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New DrugsEffect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
P2860
Q26739475-A7111346-266B-43B3-A8F1-54742D5DB8BEQ26752815-1A90CD6E-CD72-46F3-A7B2-5FC124A7EC87Q26782225-0F12A5B8-AE35-41E3-8481-D46EAD37DCBAQ28072939-7D41E039-D2BD-4F4A-9AC7-65872BFCA50FQ28073342-447EDE10-05E4-48E8-9849-36243C34C94DQ28079134-53D622D4-6D84-415D-A240-E5DDFB32C5A4Q28080114-75104C39-256F-4961-87EC-C4AE316FC9A8Q28082343-24986EDA-70CF-4AA3-B282-11C9BE6B9C15Q28085593-1052D1B7-8A90-42EC-B5D9-C1BC3D5BE887Q28553482-6B6183A8-2330-48E8-A74E-71E27F66D441Q30248634-15796323-48D5-49D9-93F8-356420379124Q31117903-F93A09E0-51DE-4BF8-81D9-933C6971FE10Q32186373-815B21DC-125F-43A9-9E27-D42B736BA2E9Q33166813-E6A5EDAB-0FEA-4697-BBE4-70C6DB3A1388Q33633674-B6829CCC-AEA6-4842-9C4C-015ECC23A387Q33732593-CE4BE807-1FC1-4FE2-BDA6-44759BADA817Q33871321-E3FB4885-0636-4E26-924F-57B60C4C5A5BQ33874679-436DEEA9-669C-47BA-8546-232A6902B6E6Q33913060-4F45259E-B6DE-425A-AFE9-6C96F0DC5F5EQ34198692-E4FFCE6F-D47F-4F0F-A537-9AB18F050155Q34613015-3A79241C-DA68-49DD-8351-E0F51C65EB24Q34710819-CF97EB9F-BB23-4D75-96AB-17762B4CDC48Q34726437-696C711E-7992-4CB3-BBB6-23F328BB4612Q34973750-4D526153-0EC6-48E7-B14D-1992DC20D249Q35064363-80B64E37-D072-448F-8386-3EE23EBBFEEEQ35157497-5B141982-B52F-4069-B81A-FE768B4877FCQ35181821-ABBFAFAD-33D0-4F3C-8027-DB5608C6339FQ35528766-10A92F11-8DEC-49BC-9B2A-9A3FE153BB73Q35780861-AEF8F202-8930-48E3-A293-332A03564B3BQ35887931-D1264871-5A6F-4840-B3DF-A1A496E3EDF1Q36059244-F81EC76D-1D07-4200-84D2-283D8B26DC7EQ36277881-44599508-AB66-45E9-B214-BDA4E529674DQ36341246-FA38FA8E-53CA-4050-B9D5-06443E583063Q36345951-13F822DB-2387-4B5E-B391-370B2BF904D4Q36599869-019478E9-33E4-493E-B75C-46D42FA24C6FQ36638899-A8BDB6F2-3C8F-4A82-9E22-7832A284DC5CQ36712216-93FFF227-6494-4E78-BBB7-FF0F4DAA869DQ36820604-5F5EC16F-03BD-4013-8E75-8B790D2D8875Q36851156-1B0715AD-8D12-4859-BC60-E2346F7FCE7AQ37075620-2C15B6BC-8213-4B9D-9CA5-4CB733CCFA01
P2860
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@en
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@nl
type
label
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@en
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@nl
prefLabel
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@en
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@nl
P2093
P2860
P921
P356
P1476
Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.
@en
P2093
D de Zeeuw
H J Lambers Heerspink
P2860
P304
P356
10.1111/DOM.12127
P577
2013-06-05T00:00:00Z